HanX Biopharmaceuticals (3378.HK)

Executive Summary

HanX Biopharmaceuticals is a clinical-stage biotechnology company focused on developing innovative antibody-based therapeutics for oncology and immunology. Founded in 2020 and headquartered in Wuhan, China, the company leverages proprietary antibody technology platforms to target key immune checkpoints such as PD-1 and CD47. Its lead programs are directed at triple-negative breast cancer (TNBC) and hematological malignancies, areas of high unmet medical need. The company went public on the Hong Kong Stock Exchange (ticker: 3378.HK) and is currently valued at approximately $3.9 billion, reflecting investor confidence in its pipeline and technology. HanX's most advanced candidates are in Phase 2 clinical trials, with initial data expected in the coming months. The TNBC program aims to address a challenging cancer subtype with limited treatment options, while the CD47-targeted therapy has potential in blood cancers where macrophage checkpoint inhibition is a promising approach. The company's strong financial position and focused pipeline position it for potential value creation, though clinical execution and competitive dynamics remain key risks. Upcoming catalysts include key data readouts and potential partnership opportunities that could validate its platform and drive further growth.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead PD-1 antibody in triple-negative breast cancer60% success
• Q3 2026Phase 2 data readout for CD47 antibody in hematological malignancies55% success
• Q3 2026Potential licensing or partnership deal for CD47 or PD-1 programs40% success